

# Analysis of the cystic fibrosis transmembrane conductance regulator (*CFTR*) gene, in patients with alcoholic liver disease (ALD) and alcoholic chronic pancreatitis (ACP)

Gangwani A<sup>1</sup>, Jain MK<sup>2</sup>

<sup>1</sup>Dr Amar Gangwani, Assistant Professor, Department of Pathology, Bundelkhand Medical College, Sagar, MP, <sup>2</sup>Dr Manish Kumar Jain, Department of Zoology, Dr .H.S. Gaur University, Sagar, MP, India

**Address of Correspondence:** Dr Amar Gangwani, **Email:** drgangwaniamar79@gmail.com

## Abstract

**Introduction:** Cystic fibrosis (CF) is an autosomal recessive disorder affecting multiple organs. A defective *CFTR* gene leads to inadequate transport of Cl ions between intra- and extracellular environment of cells in affected organs. Susceptibility to alcoholic chronic pancreatitis (ACP) could be genetically determined. Mutations in cystic fibrosis transmembrane conductance regulator (*CFTR*) genes have been variably associated with both hereditary and idiopathic form of chronic pancreatitis (CP). Our aim was to analyze these genes in ACP patients. Mutational screening was performed in 05 unrelated ACP patients and 05 patients with alcoholic liver disease (ALD). **Method:** Patients with ACP and ALD, were admitted in Bundelkhand Medical College hospital, Sagar, and enrolled for genetic analysis. Genomic DNA was extracted from whole blood according to the established protocols using the DNA Isolation Kit for Mammalian blood (Genei Bangalore). **Results:** Mutation analysis of *CFTR* was performed in all ACP and ALD patients. In three ACP patients,  $\Delta F508$  mutation was detected in heterozygous state with a prevalence rate of 8.88%. R117 H was another mutation detected in ACP patients in heterozygous state. **Conclusion:** Present study was performed to determine whether patients with ACP and ALD had mutations in the *CFTR* gene and to explore whether non coding sequences that produce low levels of *CFTR* mRNA (the 5T allele) was responsible for above mentioned abnormalities. Our hypothesis was that the pancreatic damage due to high alcohol intake could be due to abnormal allele or a combination of multiple mutations occurring in the two alleles in *CFTR* gene.

**Keywords:** Alcohol, Cystic Fibrosis, Alcoholic Chronic Pancreatitis (ACP), Acute Liver Disease (ALD)

## Introduction

Cystic Fibrosis (CF) is an autosomal recessive genetic disease that was first described in 1936 by the Swiss pathologist, Guido Fanconi, who reported the autopsy and clinical characteristics of three patients with bronchiectasis and pancreatic insufficiency [1]. In 1938, Dr Dorothy Anderson published an autopsy study of 38 infants, described the findings as “cystic fibrosis of the pancreas” and recognized the syndrome as an inherited disease [2].


Chronic pancreatitis (CP) is a potentially life-threatening disease characterized by a progressive inflammatory disorder ultimately leading to irreversible

morphological changes and permanent impairment of exocrine and endocrine functions. Most patients with CP suffer from relapsing attacks of abdominal pain and are at a markedly increased risk of developing maldigestion, diabetes mellitus, and pancreatic cancer [3]. Alcoholism is the most common etiologic factor in up to 70% of patients with CP. Other causes include drugs, duct-obstructing lesions, and metabolic or autoimmune disorders [2]. In the rare form of hereditary pancreatitis (HP), at least two major mutations (*R122H* and *N29I*) in the cationic trypsinogen gene (protease, serine 1, *PRSSI*) have been identified. *In vitro* biochemical studies suggest that these two mutations and additional pancreatitis-associated *PRSSI* mutations [4] may inhibit autolysis of trypsin and or enhance autoactivation of trypsinogen, resulting in a gain of trypsin.

Manuscript received: 6<sup>th</sup> Nov 2015  
Reviewed: 14<sup>th</sup> Nov 2015  
Author Corrected: 30<sup>th</sup> Nov 2015  
Accepted for Publication: 11<sup>th</sup> Dec 2015

In up to 30% of patients, association with any of the aforementioned factors is lacking and the disease is classified as idiopathic (ICP). Some evidence exists that at least in a small proportion of patients with ICP, a mutation of one or both alleles of either the cystic fibrosis transmembrane conductance regulator (*CFTR*) gene [5, 6]. Severe mutations in both alleles of the *CFTR* results in the commonly recognized cystic fibrosis (CF) having clinical features of abnormal sweat chloride concentrations, pancreatic insufficiency, and progressive pulmonary disease. Among CF patients,

two-thirds have a deletion of three-base pair between the nucleotides 1652 and 1655 with subsequent deletion of the phenylalanine amino acid at codon 508 ( $\Delta F508$ , Fig.1), although approximately 1000 other mutations have been reported. Most *CFTR* mutations can be classified according to a 15 severity category system based on the presumed or demonstrated molecular consequences. Typical CF patients with severe pancreatic impairment tend to have two severe mutations (i.e, class I, II, or III), whereas CF patients with pancreatic sufficiency from birth tend to have at least one CF 'mild allele' (ie, class IV or V).(7)].



**Figure 1: The  $\Delta F508$  deletion is the most common cause of cystic fibrosis. The isoleucine (Ile) at amino acid position 507 remains unchanged because both ATC and ATT code for isoleucine**

*SPINK1* is a peptide that is synthesized by pancreatic acinar cells and co localizes with trypsinogen in the zymogen granules. *SPINK1* acts as the first line of defence against prematurely activated trypsinogen in the acinar cells by physically blocking the active site of trypsin. The most known mutation (*N34S*) of the *SPINK1* gene is relatively common (up to 4% of general population) and markedly increased (up to 25%) in ICP patients [7]. The discovery of gene mutations that induce or predispose to CP led some researchers to investigate about a possible causal role of genetic factors in the occurrence and development of alcoholic chronic pancreatitis (ACP). Evidence for a genetic basis for ACP comes from epidemiological, laboratory, and clinical studies: only about 5-10% alcoholics suffer from clinically recognized CP. Although a linear correlation exists between the risk of developing CP and the quantity of alcohol consumption, there is no apparent threshold of toxicity. Long-term, high-dose alcohol feeding of laboratory animals fails to cause CP. To date, most of the relevant studies in ACP performed mutation analysis of one single gene that is *CFTR*. Moreover, due to differences in the selection and number of participants and the mutation screening method used, the reported mutation rates observed in one single gene i.e *CFTR*, varied greatly among different studies. A simultaneous analysis of all three genes in patients with ACP would provide insights into the relative contribution of each gene to the etiology of this disease.

The aim of this study was to perform this kind of analysis by screening the most relevant mutations of the *CFTR* genes in patients (of Sagar District) with ACP. As controls, we screened patients from the same geographical area who were affected by alcoholic liver disease (ALD) without a clinically recognized pancreatic disease.

## Materials and Methods

Patients with ACP and ALD, who were consecutively admitted in Govt. District Hospital associated hospital of Bundelkhand Medical College, Sagar were enrolled for genetic analysis.

**DNA Extraction:** Genomic DNA was extracted from whole blood according to the established protocols using the DNA Isolation Kit for Mammalian blood (Genei Bangalore).

**Mutation Screening of the CFTR gene:** Most frequent mutation ( $\Delta F508$ ) was examined with the polymerase chain reaction (PCR) followed by an ARMS. Identification of unknown mutations was done by Single Strand Conformational Polymorphism (SSCP) analysis (Applied Biosystems). The *CFTR* polymorphic intron 8 poly T region was analyzed according to the method described by Chillon *et al* [7].

**Statistical Analysis:** Student's *t*-test was used for age, age at symptoms' onset, symptoms' duration, and alcohol consumption. Pearson's  $\chi^2$ -test was used for sex and smoking habits. Comparison of mutation frequency between ACP and ALD patients was performed by means of Fisher's exact test (expected values lower than 5 per cell). A *P*-value less than 0.05 were considered to indicate statistical significance.

## Results

**Patients:** A total of 10 unrelated patients (05 males; mean age: 38 years) with ACP and 05 patients ( 5 males; mean age: 44 years) with ALD were studied. We did not find any significant difference between the two groups of patients as far as alcohol consumption and smoking habits was considered. Furthermore, no specific association was observed between any demographic or clinical subjects' characteristics and gene mutations (Table 1).

**Table 1: Sequence variations identified in the *CFTR* genes in 05 ACP patients**

<i>CFTR</i>		
<i>Patient</i>	<i>Mutation</i>	<i>IVS8 (Poly T variant)</i>
1	R117H	U
2	$\Delta F508$	7T/9T
3	$\Delta F508$	7T/7T
4	R117H	7T/7T
5	$\Delta F508$	7T/7T

U- Unidentified

**Table 2: Sequence variations identified in the *CFTR* genes in 05 ALD patients.**

<i>CFTR</i>		
<i>Patient</i>	<i>Mutant</i>	<i>Poly T</i>
1	—	ND
2	—	7/7
3	N1303K	7/7
4		5/7
5	—	5/5

ND, not done due to insufficient DNA sample

**Mutation analysis of the CFTR gene:** Mutation analysis of *CFTR* was performed in all ACP patients and in all ALD patients. In three ACP patients,  $\Delta F508$  mutation was detected in heterozygous state (Table 1) with a prevalence rate of 8.88%. This prevalence was different from the expected prevalence of 3.22% ( $P=0.64$ ) in our geographical area. R117H was another mutation detected in two ACP patients in heterozygous conditions. No patient with ACP carrying *CFTR* mutations had the 5T allele (Table1). A single mutation, N1303K, in the heterozygous state, was detected in one ALD patient (suffering from CP) with a prevalence rate (3.03%) more than that expected in the general population.

## Discussion

Moreover, one would speculate that an alcoholic drinker who simultaneously carries a major mutation of the *CFTR* gene in one allele and a minor mutation of the same gene in the other allele is likely to be more affected by an atypical form of CF with CP than ACP. In the present study, the prevalence of mutations of *CFTR* in ACP patients was similar to that observed in ALD and more than expected in normal population from the same geographical area.

The lack of a significant difference in the prevalence of gene mutations between ACP and ALD patients could be affected by a beta error due to the small sample size.

The main objectives of this study was to determine whether patients with Acute Chronic Pancreatitis (ACP) and Acute Liver Disease (ALD) had mutations in the *CFTR* gene and to explore whether non coding sequences that produce low levels of *CFTR* mRNA (the 5T allele) was responsible for above mentioned abnormalities. In the present study, our hypothesis was that the pancreatic damage due to high alcohol intake could be due to abnormal allele or a combination of multiple mutations occurring in the two alleles in *CFTR* gene (compound heterozygote). This hypothesis has already been successfully tested in both ICP and tropical calcific pancreatitis (TCP). The latter is an idiopathic, juvenile, nonalcoholic form of CP widely prevalent in several tropical countries. By simultaneously analyzing 39 ICP subjects for common mutations of *CFTR*, *SPINK1*, and *PRSS1*, Noone *et al* (2001) (8) found that about 60% of their patients had at least one mutation in either *CFTR* or *SPINK1*, or both. Interestingly, the risk of pancreatitis was increased approximately five-fold by having one *CFTR* mutation, 20-fold by having *SPINK1* N34S mutation, 40-fold by having two *CFTR* mutations (compound heterozygotes), and 900-fold by having N34S and two *CFTR* mutations. By using a similar approach, [9] found that at least 30% of 39 French patients with ICP carried at least one abnormal allele in one of the three genes, with a compound heterozygote state for *CFTR* in four patients and a trans-heterozygote state for *SPINK1/CFTR* genes in other three patients. The 5T allele causes reduced levels of normal *CFTR* mRNA [10], this DNA variant would appear likely to be involved in the pathogenesis of ACP and ALD. Future studies should be designed with large sample sizes

including healthy controls in order to avoid potential shortcomings.

## Conclusion

The pathogenesis of ACP is still an unresolved problem. Several different theories have been made such as duct obstruction by protein plugs, direct toxicity of ethanol, and oxidative stress. However, none of these mechanisms has yet found a solid experimental support to gain wide acceptance. As already mentioned, evidence for a genetic basis for ACP comes from epidemiological, laboratory and clinical studies. Although susceptibility to alcoholic pancreatic damage could be inherited, until now no clear association between any gene mutation(s) and occurrence of ACP in alcoholics has been found. In particular, during the last few years, three single genes (*PRSS1*, *CFTR* and *SPINK1*) have been investigated in patients with ACP.

In summary, this study shows that mutations in *CFTR* genes are occasionally found in patients with ACP, but their prevalence is not significantly increased in comparison with alcoholics who develop ALD without clinical, biochemical, or radiological signs of CP. Regarding the 5T allele, our data are in agreement with the findings of Sharer *et al.* (1998) and Cohn *et al.* (1998) and indicate that this allele does not confer a significant risk of chronic pancreatitis. The agreement of these studies is important from a public health standpoint because the 5T allele is the most common disease associated polymorphism in the *CFTR* gene described to date in the general population. The role of *CFTR* in chronic pancreatitis is as yet unknown. Studies performed so far have not explored the whole gene and have focused on mutations involved in Cystic Fibrosis.

**Funding:** Nil. **Conflict of interest:** Nil.

**Permission for IRB:** Yes

## References

1. Fanconi, G., Wehlinger, E. and Knauer C. Das (1936) Coeliakie-Syndrom bei bronchiectasien. *Wien Med Wochenschr* 86, 753-756.
2. Anderson, D.H. (1938). Cystic fibrosis of the pancreas and its relation to celiac disease: A clinical and pathological study. *Am. J. Dis. Child* 56, 344-349

3. Williams SG, Westaby D, Tanner MS, Mowat AP. Liver and biliary problems in cystic fibrosis. *Br Med Bull.* 1992 Oct;48(4):877-92.
4. C.F.F. (2003, 2004,2006) Cystic Fibrosis Foundation Patient registry. *Annual Data Report.* Toronto, Canada.
5. Sharer N, Schwarz M, Malone G, Howarth A, Painter J, Super M, Braganza J. Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. *N Engl J Med.* 1998 Sep 3;339(10):645-52.
6. Cohn JA, Strong TV, Picciotto MR, Nairn AC, Collins FS, Fitz JG. Localization of the cystic fibrosis transmembrane conductance regulator in human bile duct epithelial cells. *Gastroenterology.* 1993 Dec;105(6):1857-64.
7. Chillón M, Casals T, Mercier B, Bassas L, Lissens W, Silber S, Romey MC, Ruiz-Romero J, Verlingue C, Claustres M, et al. Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. *N Engl J Med.* 1995 Jun 1;332(22):1475-80.
- 8.Noone PG, Zhou Z, Silverman LM, Jowell PS, Knowles MR, Cohn JA. Cystic fibrosis gene mutations and pancreatitis risk: relation to epithelial ion transport and trypsin inhibitor genemutations. *Gastroenterology.* 2001 Dec;121(6):1310-9.
9. Audrézet MP, Chen JM, Le Maréchal C et al: Determination of the relative contribution of three genes, the cystic fibrosis transmembrane conductance regulator gene, the cationic trypsinogen gene, and the pancreatic secretory trypsin inhibitor gene, to the etiology of idiopathic chronic pancreatitis. *Eur J Hum Genet* 2002; 10: 100–106.
10. Chu CS, Trapnell BC, Curristin S, Cutting GR, Crystal RG. Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA. *Nat Genet.* 1993 Feb;3(2):151-6.

.....  
**How to cite this article?**

Gangwani A, Jain MK. Analysis of the cystic fibrosis transmembrane conductance regulator (*CFTR*) gene, in patients with alcoholic liver disease (ALD) and alcoholic chronic pancreatitis (ACP). *Int J Med Res Rev* 2015;3(11):1353-1357. doi: 10.17511/ijmrr.2015.i11.245.

.....